Ms Wood is expected to lead the pioneering business through an anticipated period of transformational growth both in terms of entering new areas of research and geographic expansion.

She joins the world-renowned neurological research business from Clyde Munro where she held a number of senior leadership positions including her most recent role as COO. She brings a wealth of experience and a proven track record of excellence within both the NHS and the private healthcare sector.

In addition to the new facility in England expected to open in Q3 this year, Fiona’s appointment comes at an exciting time for NeuroClin following a further seven figure investment made earlier this year by its main backer, N4 Partners, alongside previous investments into the business by Foresight Group and Fullbrook Thorpe Investments.

Since launching in 1999, NeuroClin has been at the forefront of global research on an array of complex neurological conditions such as Alzheimer’s, Parkinson’s, dementia and depression, offering its participants access to ground-breaking treatments currently being developed to help combat neurodegenerative diseases across the globe.

On her appointment as NeuroClin’s new CEO, Ms Wood, said: “I’m excited to embark on this new chapter at NeuroClin.

“It’s great to announce our plans for a new site in England and my focus will be to work with the experienced team to further execute our growth and expansion strategy, unlocking further opportunities within the field of clinical research and continue to cement NeuroClin’s reputation as one of the world’s leading neurological research centres.”

Jeff Thomis, NeuroClin’s chair, added: “It has been very encouraging to see the progress NeuroClin has made in continuing to build on its global reputation and further diversify the research base. A strong platform has been developed and, under Fiona’s leadership, we look ahead to further expansion.”